The University of Nebraska-Lincoln Biological Process Development Facility (BPDF) is a leading research laboratory in the development of vaccines and therapeutic agents from recombinant proteins.
The BPDF provides public and private sector clients with process research and early manufacturing of new therapeutic molecules for human clinical testing.
The BPDF offers state-of-the-art equipment, pilot-scale facilities and expert scale-up assistance that is time and cost effective. BPDF is uniquely qualified to offer this assistance, offering facilities and personnel that can optimize an entire process from the bench top to the final bulk product.
A large portion of the BPDF's work is in the development of vaccines against biological warfare agents and products that can be used as therapeutic countermeasures to treat people who have been exposed to biological agents.
The BPDF provides these advantages in vaccine/therapeutic agent development:
- Recognized as the leading expert in the recombinant expression system ( Pichia pastoris ), which is used to express the Botulinum vaccines
- One of the few University facilities working in the area of recombinant proteins for vaccines against biological warfare agents
- Focuses on Phase I/II clinical material, allowing rapid development of new processes and production of therapeutic proteins